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Regenerative medicine strategies for restoring articular cartilage face signiﬁcant challenges to recreate
the complex and dynamic biochemical and biomechanical functions of native tissues. As an approach to
recapitulate the complexity of the extracellular matrix, collagen-mimetic proteins offer a modular
template to incorporate bioactive and biodegradable moieties into a single construct. We modiﬁed a
Streptococcal collagen-like 2 protein with hyaluronic acid (HA) or chondroitin sulfate (CS)-binding
peptides and then cross-linked with a matrix metalloproteinase 7 (MMP7)-sensitive peptide to form
biodegradable hydrogels. Human mesenchymal stem cells (hMSCs) encapsulated in these hydrogels
exhibited improved viability and signiﬁcantly enhanced chondrogenic differentiation compared to
controls that were not functionalized with glycosaminoglycan-binding peptides. Hydrogels functional-
ized with CS-binding peptides also led to signiﬁcantly higher MMP7 gene expression and activity while
the HA-binding peptides signiﬁcantly increased chondrogenic differentiation of the hMSCs. Our results
highlight the potential of this novel biomaterial to modulate cell-mediated processes and create func-
tional tissue engineered constructs for regenerative medicine applications.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Articular cartilage is a complex connective tissue covering the
surfaces of bones in synovial joints [1] that enables low-friction
articulation and helps transmit and distribute forces to the sub-
chondral bone [2]. It is characterized by a depth-dependent zonal
organization and biochemical microenvironment that is vital for its
multiple functions [3]. The avascular and aneural nature of articular
cartilage contribute to its limited capacity for self-repair following
trauma or disease. Current clinical treatments to induce articular
cartilage tissue repair, such as autologous chondrocytes, Imperial College London,
tevens).
generative Medicine, Depart-
ska Institutet, Scheeles v€ag 2,
Ltd. This is an open access articleimplantation, mosaicplasty, andmicrofracture, often provide short-
term pain relief and recovered joint mobility, but the long-term
beneﬁts remain elusive. The resulting repaired tissue does not
exhibit the same biomechanical behavior as that of native articular
cartilage and eventually breaks down, requiring additional treat-
ment such as total joint arthroplasty [1,3,4]. As a result, research
into the development of bioengineered constructs, with the aim to
provide an adequate cellular environment to favor the regeneration
of damaged or diseased articular cartilage, has gained momentum
in recent years [5e10]. The ability to engineer tissues that mimic
the complex native articular cartilage composition and architecture
holds great promise towards restoring the unique biomechanical
behavior and function necessary for long-term success.
Strategies for cartilage tissue engineering typically use a com-
bination of biomolecules and biomaterials to provide the appro-
priate signaling and support for speciﬁc cell types [5e9,11].
Hydrogels are three-dimensional (3D) water-based matrices that
can be engineered to incorporate bioactive cues and beunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ronment reminiscent of the native tissue for encapsulated cells
[14]. Poly(ethylene glycol) (PEG) [12e16] hydrogels have been used
extensively for cartilage tissue engineering applications because of
their bio-inert nature and versatility. Bioactivity has been intro-
duced into this system through the inclusion of growth factors such
as transforming growth factor b3 (TGF-b3) [11] and peptides
[10,17e19] tomarkedly enhance the functional outcome. Hydrogels
derived from hyaluronic acid (HA) [17] and collagen [18] have also
been used for cartilage tissue engineering applications because
they are commonly found in native articular cartilage extracellular
matrix (ECM). These hydrogels can be degraded in vivo but are
typically cross-linked with non-degradable cross-linkers that can
affect their degradation behavior [12,14,15,17]. Biodegradable
hydrogels are an attractive approach for cartilage tissue engineer-
ing because they offer a temporary support structure for encapsu-
lated cells but can be degraded in conjunction with the deposition
of neo-cartilaginous matrix [15,20,21]. Ideally, a hydrogel would
degrade at a rate that allows it to provide adequate support to cells
without restricting the matrix deposition and remodeling [17].
The incorporation of hydrolytically or enzymatically cleavable
substrates are the most common approaches used to impart
biodegradability within hydrogel systems [20]. A major drawback
of hydrolytically degradable hydrogels is the lack of control over
degradation kinetics since the degradation mechanism is not spe-
ciﬁc. Enzymatically cleavable sites take advantage of cell-mediated
processes that can naturally break down the construct, allowing for
improved spatiotemporal control of cell migration, degradation,
and matrix deposition. Speciﬁc enzyme-sensitive peptides, for
example, can be included in the hydrogel network to enable
localized cell-induced degradation. Matrix metalloproteinases
(MMPs) are often targeted as the route of enzymatic degradation
since they are known to be involved in the cleavage of ECM com-
ponents during native tissue remodeling [13,15,20,22e26]. In
articular cartilage, MMPs are involved in the turnover of several
matrix components including collagen type II and aggrecan, which
aid in cell tissue development and remodeling [13,15]. MMP7 is
thought to play a role in chondrogenesis by controlling the
bioavailability of chondrogenic factors and facilitating collagen type
II maturation [20]. Recently, MMP7-cleavable peptide substrates
(MMP7) were developed and incorporated into PEG hydrogels and
shown to degrade via MMP7 secreted by encapsulated human
mesenchymal stem cells (hMSCs) during chondrogenesis [20].
Here, we have developed MMP7-degradable hydrogels based on
recombinant Streptococcal collagen-like 2 (Scl2) proteins and
functionalized with glycosaminoglycan (GAG)-binding peptides.
Scl2 proteins contain the characteristic repeating (Gly-Xaa-Yaa)n
residues that assemble into the triple helical conformation found in
mammalian collagens. However, unlike mammalian collagens,
these proteins inherently lack cell-binding sites and thereby pro-
vide a structurally sound biological blank slate by which to sys-
tematically integrate speciﬁc motifs for a desired cellular response
[27e32]. In addition, Scl2 proteins are produced recombinantly
with minimal batch-to-batch variation in predictability of perfor-
mance, purity, and quality [27e31]. Previously, Scl2 proteins with
integrin-binding sequences have been used in PEG-based hydrogels
to bind endothelial and smoothmuscle cells for vascular grafts [29].
Here, a blank slate Scl2 protein was cross-linked with the MMP7-
sensitive peptide to form hydrogels and functionalized with pep-
tides that bind hyaluronic acid (HA) and chondroitin sulfate (CS)
(Fig. 1). Our group recently showed that the HA-binding (HAbind)
and CS-binding (CSbind) peptides can speciﬁcally and dynamically
bind HA and CS, respectively, mimicking native ECM-like in-
teractions [10]. In the current work, we investigated how GAG-
binding peptides affect the chondrogenic differentiation of hMSCsencapsulated within the hydrogels that could then be implanted to
treat focal defects, MMP7 gene expression and activity. These
hydrogels also offer the potential for a less invasive, injectable
approach to stimulate chondrogenesis in host MSCs. Moreover,
these versatile hydrogels have the potential to incorporate multiple
and different peptides to speciﬁcally tune bioactivity and biode-
gradability, that can be tethered from the protein backbone to
mimic the complexity of native ECM.
2. Materials and methods
2.1. Materials
All chemicals were used as provided by the manufacturers. Poly(ethylene gly-
col)-acrylate-N-hydroxysuccinimide (2000 g/mol) (PEG-acrylate-NHS) was pur-
chased from JenKem Technology (Allen, Texas, USA). Rink amide resin, Fmoc-
protected amino acids, N, N dimethyl formamide (DMF), dichloromethane (DCM),
20% (v/v) piperidine in DMF, O-benzotriazole-N,N,N'N'-tetramethyluronium-hexa-
ﬂuoro-phosphate (HBTU), and diisopropylethylamine (DIEA) were purchased from
AGTC Bioproducts (Hessle, UK). MMP7 ﬂuorogenic substrate was purchased from
Merck Millipore (Nottingham, UK). All other chemicals were purchased from Sig-
maeAldrich (Milwaukee, WI, USA). Recombinant Scl2 protein was expressed in
Escherichia coli BL21-DE3 and puriﬁed as previously described [30]. Recombinant
Scl2 protein was dialyzed against phosphate-buffered saline (PBS), pH 7.4, and
protein concentration was determined using a calculated extinction coefﬁcient.
2.2. Peptide synthesis and puriﬁcation
The HAbind (CGGGRYPISRPRKR), CSbind (CGGGYKTNFRRYYRF), MMP7
(CGGGPLELRAGGGC), and scrambled MMP7 (ScrMMP7; CGGGPALLREGGGC) pep-
tides were synthesizedmanually on a 2mmol scale using standard Fmoc solid phase
peptide synthesis techniques as previously described [10]. For each coupling, the
Fmoc protecting group was removed with 20% (v/v) piperidine in DMF followed by
washing with DCM and DMF. Amino acids were activated by adding 4 molar
equivalent of each Fmoc protected amino acid to 3.95 molar equivalent of HBTU and
dissolved in DMF. Six molar equivalent of DIEAwas added to the amino acid solution
and the coupling solution added to the resin. The coupling reaction was allowed to
proceed for two to three hours before the resin was washed in DCM and DMF.
Ninhydrin tests were performed after each Fmoc deprotection and coupling step to
monitor the presence of free amines. Once the synthesis was completed, the pep-
tides were cleaved in 95% (v/v) triﬂuoroacetic acid (TFA), 2.5% (v/v) triisopropyl
silane (TIS), and 2.5% (v/v) H2O for four hours. TFA was removed using rotary
evaporation, and the peptide residue was precipitated and washed with cold diethyl
ether (DEE) by centrifugation. The peptide precipitatewas then allowed to dry under
vacuum to remove residual ether. The peptide was puriﬁed (Fig. S1) using reversed
phase preparative high performance liquid chromatography (HPLC; Shimadzu) in an
acetonitrile/water gradient under acidic conditions on a Phenomenex C18 Gemini
NX column (5 mm pore size, 110 Å particle size, 150  21.2 mm). Following puriﬁ-
cation, the peptide was lyophilized on a freeze dryer (Labconco) for storage prior to
use. The puriﬁed peptide mass was veriﬁed by matrix assisted laser desorption
spectroscopy (MALDI; Waters).
A cyclic RGDS peptide (GRGDSC) was synthesized at a 1 mmol scale on a 2-
chlorotrityl chloride resin (100e200 mesh; VWR). Fmoc-Cys(Trt)-OH (Nova-
biochem) was dissolved at 1 molar equivalent in DCM with a small amount of DMF
added until fully solubilized. Half the solution was added to the resin along with
500 mL of DIEA for 15 min shaking on a wrist action shaker. This was repeated with
the remaining solution followed by thorough washing with DMF and DCM. A
ninhydrin test was performed to monitor the coupling by detecting the presence of
free amines. The remaining free amines were capped by adding a solution of 5% (v/v)
acetic anhydride (Sigma) with 2.5% (v/v) DIEA in DMF for 10 min with shaking, and
repeated with 5 min shaking using fresh solution. The resin was then washed
thoroughly with DCM and DMF before the ninhydrin test. The Fmoc protecting
groupwas removed as described above and Fmoc-Asp(Otbu)-Ser(psiMe, Mepro)-OH
(Merck) was coupled at 2 molar equivalents with 1.95 molar equivalents of HBTU
and 3 molar equivalents of DIEA in DMF. The remaining free amines were capped,
and all other amino acids were coupled as described above. The protected peptide
was cleaved from the resin by adding 10 mL of 5% (v/v) TFA in DCM for 10 min with
shaking. The solution was drained into a round bottom ﬂask and the resin rinsed
with DCM until the solution in the synthesis vessel was clear. The DCM and TFAwere
removed carefully by rotary evaporation, leaving approximately 40 mL of solution to
avoid cleaving the protecting groups from the peptide. Ammonium hydroxide
(10 mL) was added to neutralize the TFA followed by acetonitrile to increase peptide
solubility. The protected peptide (Fig. S2 and S3) was puriﬁed by reversed phase
preparative HPLC running a mobile phase gradient of 80% ultrapure H2O and 20% (v/
v) ACN to 100% (v/v) ACN with 0.1% (v/v) TFA. The solvent was removed by rotary
evaporation until the protected peptide was completely dry, and then re-dissolved
in DMF at 1 mg/mL. The peptide was cyclized by adding 2 equivalents of benzo-
triazol-1-yl-oxytripyrrolidinophosphonium hexaﬂuorophosphate (PyBop; AGTC
Bioproducts) and 3 equivalents of DIEA overnight. The DMF was removed by rotary
Fig. 1. (A) Schematic diagram of peptide-functionalized Scl2 protein hydrogels. The terminal ε-amines of lysines on the Scl2 proteins were modiﬁed with a heterobifunctional linker
using NHS-ε-amine conjugation chemistry to generate acrylate-functionalized Scl2 proteins. The peptides (B) HAbind, (C) CSbind, (D) RGDS and (E) MMP7 were conjugated to the
acrylated Scl2 proteins via thiol-acrylate reactions.
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solubilized and puriﬁed by HPLC as described above. The remaining protecting
groupswere removed using 95% (v/v) TFAwith 2.5% (v/v) H2O and 2.5% (v/v) TIS. The
peptide was precipitated in cold DEE and puriﬁed by HPLC. Liquid chromatography-
mass spectrometry (LC-MS) was performed on an Agilent 6130 Quadrupole LC-MS
coupled to an Agilent 1260 Inﬁnity LC using a 150  4.6 mm Phenomenex Gemini
NX C18 column with a 5 mm pore size and 100 Å particle size. Ultrapure H2O and
acetonitrile each containing 0.1% (v/v) formic acid (VWR) by volume were used for
the mobile phase at a ﬂow rate of 1 mL/min. The peptide was eluted with a gradient
of 95% (v/v) H2O to 95% (v/v) acetonitrile over 11 min. The electrospray source was
operated with a capillary voltage of 3.2 kV and a cone voltage of 25 V with nitrogen
used as the nebulizer and desolvation gas at a total ﬂow of 600 L/h. Although cyclic
GRGDSC did not stick to the column, electrospray ionization (ESI) of an early elution
conﬁrmed the correct mass.
2.3. Streptoccocal collagen-like 2 (Scl2) protein synthesis and puriﬁcation
Blank slate bacterial (non-animal) collagen-like protein was obtained using the
Cold-shock vector (Takara Bio, Shiga, Japan) [33] for expression of pColdIII-V-CL in
E. coli following methods previously described [34]. Brieﬂy, the construct was
derived using pColdIII-163 encoding p163 polypeptide based on Scl 2.28 [35,36]. A
His6-tag sequence was introduced at the N-terminal of the p163 polypeptide
sequence and a protease cleavage LVPRGSP sequence was inserted between the N-
terminal globular domain (V) and the following collagen-like domain (CL) sequences
[34]. The pColdIII-VCL construct was expressed in E. coli BL21-DE3 strain. Cells were
grown in 2 x YTmediawith ampicillin (100 mg/mL) at 37 C, shaking at 200 rpm until
A600 reached an optical density (OD) in the range 3e6 AU. Cells were then cooled to
25 C and 1 mM isopropyl beta-D-thiogalactopyranoside (IPTG) was added to induce
protein expression. After 10 h incubation, cells were further cooled to 15 C for 14 h
after which the cells were harvested by centrifugation. For the extraction of protein,
each 1 g of cell pastewas re-suspended in 20mL of 50mM acetic acid at pH 2, and the
cells were ruptured by sonication using a Misonix S4000 instrument with a Enhance
Booster #1 probe at 30 A (instrument scale) for 30 min. The cell debris was removed
by centrifugation at 4 C and the supernatant containing the V-CL was retained. The
supernatant was kept at 4 C for 16 h and any precipitate that had formed was
removed by centrifugation. The collagen-like domain was obtained from puriﬁed V-
CL by incubating with 0.01 mg/mL protease at 4 C for 24 h to remove the V-domain.
The pH of the supernatant was then adjusted to 8 using 50 mM Na2HPO4 and 1 M
NaOH. The puriﬁed collagen-like domain was then concentrated and had its buffer
exchanged using a 10 kDa cross-ﬂow ﬁltrationmembrane (Pall Sciences). Purity was
veriﬁed by sodium dodecyl sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE)
[34,37] and MALDI mass spectrometry.
2.4. Scl2 modiﬁcation with acrylate groups
The Scl2 protein contains ~8.6 mol% lysine groups on its backbone that can be
functionalized with a heterobifunctional linker using a method previously reported
[29]. Brieﬂy, Scl2 proteinwas dispersed at 100 mg/mL in 50 mM acetic acid in H2O at
room temperature, and the pH was adjusted to 8.5 using 1 M NaOH. Approximately
33.3% of the terminal amines on the available lysines were reacted with PEG-
acrylate-NHS to generate Scl2 protein with acrylate groups (acrylate-Scl2). The re-
action was allowed to proceed for 18 h at room temperature with agitation. Excess
PEG-acrylate-NHS and any reaction by-products were removed by dialysis against
H2O overnight. The acrylate-Scl2 samples were sterile-ﬁltered, lyophilized, and
stored at 4 C prior to use.
2.5. Scl2 conjugation to GAG-binding peptides
HAbind, CSbind and RGDS peptides were conjugated to acrylate-Scl2 via thiol-
acrylate chemistry [38]. Brieﬂy, acrylate-Scl2 protein was re-suspended at
100mg/mL in 50mM acetic acid in H2O at room temperature. The pHwas adjusted to
8.5 using 1 M NaOH. The HAbind and CSbind peptides were added tomodify 5 or 10%
of the acrylates. The RGDS peptide was reacted to modify 10% of the acrylates. The
reaction was allowed to proceed for 2 h at room temperature with agitation. Un-
conjugated peptide and other reaction by-products were removed via dialysis
against H2O overnight. The functionalized Scl2 proteins (HAbind-Scl2, CSbind-Scl2,
RGDS-Scl2) were sterile-ﬁltered, lyophilized, and stored at 4 C until needed.
2.6. Characterization of functionalized Scl2 proteins
HAbind-Scl2, CSbind-Scl2, and RGDS-Scl2 were characterized using Fourier
transform infrared spectroscopy (FTIR) and cross-polarization magic-angle spinning
(CP-MAS) solid-state 13C NMR to determine conjugation efﬁciency. FTIR analysis
with a Perkin Elmer Spectrum One spectrometer was used to evaluate the conju-
gation of the linker and tethered peptides to Scl2 protein as previously described
[29]. FTIR spectra were taken with a scanning wavenumber range from 4000 to
650 cm1. CP-MAS solid-state 13C NMR analysis experiments were performed using
a Bruker Avance III 200 MHz (4.7T) spectrometer at a Larmor frequency of 50.1 MHz
and spinning speed of 8 kHz in a 4 mm rotor using a contact time of 1 ms. The
1.5 ppm peak of tetrakis(trimethylsilyl)methane was used for reference. Data were
processed with 200 Hz line broadening.Circular dichroism (CD) spectra of functionalized Scl2 proteins in H2O were
recorded on a Jasco J-715 spectropolarimeter controlled by the Jasco Spectra Man-
ager software equipped with a Jasco PTC-348WI Peltier temperature control system
using a quartz cuvette with a path length of 0.1 or 1 mm. For determining the
thermal transitions, the ellipticity at 220 nm was monitored [30] as the sample
temperature was increased from 25 to 45 C, with an average temperature slope of
10 C/h. The ellipticity was normalized to path length and number of residues and
was plotted against temperature.
2.7. Preparation of Scl2 hydrogels
To generate hydrogels, acrylate-Scl2, HAbind-Scl2, CSbind-Scl2 or RGDS-Scl2
samples were re-suspended at 100 mg/mL in chondrogenic medium (medium
deﬁned in Section 2.10) at room temperature with the pH adjusted to 8.5 using 1 M
NaOH. TheMMP7 or ScrMMP7 peptide was dissolved in 4mM triethanolamine (TEA)
in chondrogenic medium at pH 8.5 and reacted to modify 90% of the acrylates. The
resulting solutions were sterile-ﬁltered and pipetted to generate homogeneous
formation of MMP7-Scl2, HAbind-MMP7-Scl2, CSbind-MMP7-Scl2 or RGDS-MMP7-
Scl2 hydrogels.
2.8. Characterization of Scl2 hydrogels
Hydrogels were characterized using CP-MAS solid-state 13C NMR, rheology, and
compression testing. CP-MAS solid-state 13C NMR analysis was used to quantify the
conjugation of MMP7, HAbind, CSbind, and RGDS peptides to Scl2 protein as pre-
viously described. The mechanical properties of the hydrogels were studied using
oscillatory shear rheology and conﬁned compression testing. Oscillatory parallel
plate rheological measurements were performed using an Advanced Rheometer
AR2000ex with AR Instrument Software (TA instruments) ﬁtted with a Peltier
temperature control system. Samples were tested at 37 C using an 8 mm diameter
parallel steel plate. All samples were individually prepared immediately prior to
testing. Three sequential sweeps were applied; (1) time sweep for 2 h at 0.1% strain
and 6.28 rad/s angular frequency, (2) angular frequency sweep from 0.01 to 100 rad/
s at 0.1% strain and (3) strain sweep from 0.01 to 100% at 6.28 rad/s angular fre-
quency. For all samples, a compression load of 0.5 N was exerted during testing. For
all compression tests, discs 8 mm in diameter and 2 mm in thickness were prepared
from hydrogels swollen in chondrogenic medium for at least 24 h and inserted in a
conﬁned ring; dimensions were measured using digital calipers. Swollen hydrogels
were mechanically tested in compression using an Instron Model 5540 testing
machine (Norwood, MA, USA) equipped with a 50 N load cell. Samples were pre-
loaded to 0.05 N and compressed to 10% strain at a crosshead speed of 0.5%
strain/min. Compressive modulus was calculated from the linear portion of the
stressestrain curve.
2.9. hMSC culture
Bone marrow-derived hMSCs were purchased from PromoCell GmbH (Heidel-
berg). The hMSCs were seeded at 4000 cells per cm2 in T225 ﬂasks and cultured in
mesenchymal stem cell growth medium (MSCGM) (PromoCell GmbH, Heidelberg).
hMSCs were incubated at 37 C and 5% CO2 and the medium changed every three
days. The cells were harvested at 80% conﬂuency with 0.025% (w/v) trypsin-EDTA
(Sigma Aldrich, UK) in PBS, centrifuged and subcultured in MSCGM. Passage 6
hMSCs were used for all hydrogel encapsulation experiments.
2.10. Cell encapsulation and culture
hMSCs were homogeneously dispersed at 8  106 cells per mL in the pre-made
100 mg/mL acrylate-Scl2, HAbind-Scl2, CSbind-Scl2 or RGDS-Scl2 solution con-
taining chondrogenic medium (high-glucose (4.5 g/L) Dulbecco's Modiﬁed Eagle
Medium (DMEM; Invitrogen) supplemented with 0.1 mM dexamethasone (Sigma
Aldrich, UK),1% (v/v) penicillin streptomycin (Sigma Aldrich, UK), 50 mg/mL L-proline
(Sigma Aldrich, UK), 50 mg/mL ascorbate-2-phosphate (Sigma Aldrich, UK), 1 x
insulin-transferrin-selenium (ITS) Premix (BD Biosciences, Oxford, UK), and 10 ng/
mL TGF-b3 (Lonza, Slough, UK)). The MMP7 peptide was prepared in 4 mM TEA in
chondrogenic medium and mixed with the protein/cell solution. Aliquots (50 mL) of
the resultingmixturewere injected in a non-tissue culture treated 48-well plate and
allowed to gel. The hydrogels were then cultured in 1 mL of chondrogenic medium.
Hydrogels were incubated at 37 C and 5% CO2 for four weeks with the medium
changed every three days.
2.11. Degradation testing and MMP7 activity assay
Degradation of the hydrogels was determined by freeze-drying the hydrogels
and measuring the dry weight change over time, with and without encapsulated
cells. Hydrogels were prepared as previously described and incubated in chondro-
genic medium for 24 h at 37 C and 5% CO2. Cell-free hydrogels were incubated in
chondrogenic medium with exogenous MMPs (30 ng/mL) at 37 C and 5% CO2 for
one week with medium changed daily and dry weight measurements taken at each
day. Percentage weight change was normalized to day 0. Degradation by recombi-
nant human MMP1, MMP2, MMP7, and MMP13 (AnaSpec, San Jose, CA, USA) was
Fig. 2. The ellipticity of functionalized Scl2 proteins monitored at 220 nm from 25 to
45 C. Representative spectra are shown for all samples (n ¼ 3).
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(0.2 mg/mL trypsin).
Cell-seeded hydrogels were incubated in chondrogenic medium at 37 C and 5%
CO2 for four weeks, and dry weight measurements were taken after 0, 1, 3, 7, 14, 21,
and 28 days of culture. Percentage weight change corresponding to the cumulative
effect of cell proliferation, cartilage-like matrix deposition, and hydrogel degrada-
tionwas normalized to day 0. At each time point, 1 mL of mediumwas also removed,
sterile-ﬁltered, and analyzed for MMP7 activity. MMP7 activity was determined
using a ﬂuorogenic MMP7 substrate assay (Merck Millipore, Nottingham, UK) and
compared to negative control (chondrogenic medium) and positive control (re-
combinant human MMP7) according to the manufacturers' instructions.
2.12. Cell viability
hMSC-seeded hydrogels were cultured for 0, 1, 3, 7, 14, 21, and 28 days. After the
culture period, the hydrogels were washed three times in PBS and analyzed for cell
viability. The viability of cells was qualitatively assessed with a LIVE/DEAD®
Viability/Cytotoxicity Kit (Molecular Probes, Inc., Eugene, OR) according to the
manufacturers' instructions. Fluorescence confocal microscopy (Leica SP5 inverted
microscope, Leica Microsystems, UK) was used to visualize live (calcein; green) and
dead (ethidium homodimer-1; red) cells. The viability of cells in the hydrogels was
also quantiﬁed by the CellTiter-Glo® assay (Promega). This assay is based on the
luminescent signal output produced by metabolically active cells based on the level
of ATP present. All data were normalized to DNA content present at each time point.
2.13. DNA, sGAG, and hydroxyproline quantiﬁcation
hMSC-seeded hydrogels were cultured for 0, 1, 3, 7, 14, 21, and 28 days. After the
culture period, they were washed three times in PBS and digested individually in
papain digest solution (2.5 units papain/mL, 5 mM cysteine HCl, 5 mM EDTA, in PBS
(all reagents from Sigma Aldrich)) at 60 C for 24 h. Papain digests were stored
at 20 C until further analysis. Digested samples were assayed for total DNA con-
tent using the Quant-iT™ PicoGreen® Kit (Invitrogen) according to the manufac-
turers' instructions. The standard curve was generated with dsDNA (Invitrogen).
Sulfated GAG (sGAG) content was quantiﬁed using the Blyscan Kit (Biocolor,
Carrickfergus, UK) according to the manufacturers' instructions. The standard curve
was generated with bovine trachea chondroitin sulfate A (SigmaeAldrich).
Total collagen content was determined using the hydroxyproline content as a
measure of total collagen. Unlike mammalian collagens, bacterial collagens lack
hydroxyproline, which enabled us to distinguish between the collagen in the
hydrogel and new collagen formation. Digested samples were hydrolyzed in 6 N HCl
at 110 C for 18 h. The hydroxyproline content of the hydrolysate was determined
using the chloramine-T/Ehrlich's reagent assay and the color change quantiﬁed
spectrophotometrically at 560 nm [20,39]. Brieﬂy, free hydroxyproline was oxidized
using chloramine-T, resulting in the formation of pyrrole while Ehrlich's reagent
resulted in the formation of the chromophore. The standard curve was generated
with L-hydroxyproline (Sigma Chemical Co.).
2.14. Histology and immunohistochemistry of hydrogels
After 0 and 28 days of culture, hMSC-seeded hydrogels were washed three times
in PBS, ﬁxed with 4% (v/v) paraformaldehyde (Electron Microscopy Sciences, PA,
USA) for 1 h at 4 C, washed three times in PBS, permeabilized with 0.4% (v/v) Triton
X-100 (Sigma Aldrich, UK) for 1 h and washed again. Hydrogels were ﬂash frozen in
OCT (Tissue-Tek, Fisher Scientiﬁc) and cryosectioned at a thickness of 10 mm. Sec-
tions were transferred to treated slides (Superfrost Plus, Thermo Scientiﬁc) and
allowed to adhere for 24 h at 4 C. Slides were stained for deposited sGAGwith alcian
blue (pH 2.5), and for cell nuclei and matrix with haematoxylin and eosin (H&E).
Immunohistochemical staining (IHC) was performed for collagen type I
(Abcam), collagen type II (Abcam), and collagen type X (Abcam) with rabbit IgG and
PBS negative controls. Samples were pre-treated with hydrogen peroxide, an avidin
and biotin blocking kit (Vector Labs, UK), and blocked with 5% (v/v) goat serum.
Primary antibodies were incubated overnight at 1/200 in 5% (v/v) goat serum, fol-
lowed by goat-anti-rabbit secondary antibody labeled with HRP at 1:100 for 1 h,
stained with a 3,30-diaminobenzidine (DAB) kit (Vector Labs, UK) for 10 min, and
counter-stained with haematoxylin. All stained sections were dehydrated, mounted
with Histomount (Fisher Scientiﬁc, UK), and viewed on an Olympus BX51 micro-
scope equipped with an Olympus DP70 camera.
2.15. Gene expression analysis
hMSC-seeded hydrogels were cultured for 0, 1, 3, 7, 14, 21, and 28 days. After the
culture period, they were washed three times in PBS. Total RNAwas isolated using a
tissue ruptor (Qiagen) to homogenize samples with RLT buffer after which QIAsh-
redder columns (Qiagen) and the RNeasy Mini Kit (Qiagen) were used to extract the
RNA according to the manufacturers0 instructions. QuantiTect® Reverse Transcrip-
tion Kit (Qiagen) and QuantiTect® SYBR Green PCR Kit (Qiagen) were used to
perform reverse transcription and quantitative real-time polymerase chain reaction
(qPCR), respectively. Thermocycling and SYBR Green detectionwere performed on a
Corbett Rotorgene 6000 (Qiagen) with extension at 72 C and denaturing at 95 C.
Annealing temperatures varied depending on the primers. Datawere analyzed usingthe DDCT method [40]. The following primers were used: MMP7 (Forward 50-
GAGTGAGCTACAGTGGGAACA-30 and Reverse 50-CTATGACGCGGGAGTTTAACAT-30),
and TIMP2 (Forward 50-TGGACGTTGGAGGAAAGAAG-30 and Reverse 50-GGGCA-
CAATGAAGTCACAGA-30) at an annealing temperature of 52 C, GAPDH (Quiagen)
(Forward 50-TGGTATCGTGGAAGGACTCATGA-30 and Reverse 50-ATGCCAGT-
GAGCTTCCCGTTCAG-30), COL1A1 (Forward 50-CATTAGGGGTCACAATGGTC-30 and
Reverse 50-TGGAGTTCCATTTTCACCAG-30), COL2A1 (Forward 50-CATCCCACCCTCT-
CACAGTT-30 and Reverse 50-GTCTCTGCCTTGACCCAAAG-30), and ACAN (Forward 50-
CACTGTTACCGCCACTTCCC-30 and Reverse 50- GACATCGTTCCACTCGCCCT -30) at an
annealing temperature of 60 C, and SOX9 (Forward 50-AACGCCGAGCTCAGCAAG-30
and Reverse 50- ACGAACGGCCGCTTCTC-30) at an annealing temperature of 62 C.
2.16. Statistical analysis
All experimental groups had a sample size of n ¼ 3 for biochemical, qPCR, and
mechanical property analyses. All cell-related work was repeated with hMSCs from
three different donors and with each donor having a sample size of n ¼ 3. Data are
presented as means ± standard deviation (SD). Statistical signiﬁcance was deter-
mined by performing analysis of variance (ANOVA)with a signiﬁcance accepted at p-
value < 0.05, except for gene expression analysis where ANOVA with Bonferroni
correction was performed.
3. Results and discussion
3.1. Scl2 functionalization
FTIR spectroscopy was used to analyze and validate each func-
tionalization step. It showed IR transmittance peaks at 1630 cm1
(amide C]O) that were assigned to the Scl2 protein in all samples
and used for normalizing. The peak at 1110 cm1 (ether CeOeC)
assigned to the acrylate was present in the acrylate-Scl2, HAb-
ind(10%)-Scl2, CSbind(10%)-Scl2, and RGDS(10%)-Scl2 samples and
absent in the Scl2 control (Fig. S5). CP-MAS solid-state 13C NMRwas
used to quantify the conjugation density of acrylate, MMP7, HAb-
ind, CSbind, and RGDS peptides to Scl2 (Table S1 and Fig. S6). CP-
MAS analysis showed the conjugation density of acrylate and
each peptide to be at the expected value.
CD was used to observe any changes in the secondary structure
of the modiﬁed proteins as a result of the functionalization. Scl2
proteins typically form a triple helical conformation with a char-
acteristic peak at 220 nm in the CD spectra [29,34]. The addition of
the acrylate and tethered HAbind, CSbind, and RGDS peptides did
not affect the triple helical conformation, and the thermal stabil-
ities (Fig. 2) remained essentially unchanged. Formation of a
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determination difﬁcult, but cross-linking is generally seen as sta-
bilizing constructs [30].3.2. Mechanical characterization of hydrogels
For all hydrogels, the cross-linking density was kept constant to
maintain similar mechanical properties since matrix stiffness has
been shown to affect cell processes such as adhesion, proliferation,
and differentiation [41,42]. Oscillatory shear rheology conﬁrmed
gelation and was used to measure the mechanical properties of all
formulations. There were no statistical differences in time to gela-
tion or storagemoduli between the different hydrogel formulations
(Fig. 3A, B and Fig. S7). The equilibrium storage moduli of all
hydrogels remained in the linear elastic region (~8 kPa) up to
strains of 1% with minimal variation and signiﬁcantly decreased
above 10% strain. These hydrogels appear to retain sufﬁcient me-
chanical properties up to 10% strain, which corresponds with
physiologically relevant values [2e4,39]. The failure strains
(20e30%) of the hydrogels are comparable to other hydrogel-based
materials for treating focal articular cartilage defects [39,43]. Me-
chanical behavior of the hydrogels was further characterized using
conﬁned compression testing (Fig. 3C and Fig. S8). All hydrogel
formulations had similar compressive moduli of ~2.5 kPa. Since theFig. 3. Mechanical properties of functionalized Scl2 hydrogels. (A) Time to gelation at a temp
determined from strain sweep up to 1% strain at a temperature of 37 C and an angular fre
pressed to 10% strain at 0.5% strain/min. Values are represented as means ± SD. *P < 0.05hydrogels had similar mechanical properties, we were able to
compare the inﬂuence of the HAbind, CSbind, and RGDS peptides
decoupled from the mechanical properties.3.3. Degradation kinetics of acellular hydrogels
Fig. 4 illustrates the degradation of the acellular hydrogels in
the presence of recombinant human MMP7 compared to trypsin,
MMP1, MMP2, and MMP13. As expected, the hydrogels cross-
linked with the MMP7-sensitive peptide degraded faster in the
presence of MMP7 compared to when exposed to MMP1, MMP2,
and MMP13 where minimal degradation was observed (Fig. 4A)
(P < 0.05). Cleavage of the MMP7 peptide alone by exogenous
MMP7 was conﬁrmed through LCMS-ESI analysis (Fig. S4) and
suggests that the degradation of the MMP7-Scl2 hydrogels occurs
speciﬁcally through the MMP7 peptide cross-links being cleaved
by MMP7. MMP1, MMP2, and MMP13 caused small amounts of
degradation, likely because MMPs are somewhat promiscuous and
known to recognize other peptide sequences [13,20,45e47]. The
inclusion of bioactive epitopes did not signiﬁcantly affect the
degradation rate in the hydrogels, demonstrating that MMP7 ac-
tivity is not disrupted by the presence of the bioactive peptides
(Fig. 4B).erature of 37 C, angular frequency of 6.28 rad/s and strain of 0.5%. (B) Storage modulus
quency of 6.28 rad/s. (C) Conﬁned elastic modulus of compression of hydrogels com-
(n ¼ 3).
Fig. 4. Degradation of acellular hydrogels over time characterized by dry weight loss. Degradation of (A) MMP7 peptide cross-linked-hydrogels without tethered bioactive se-
quences, (B) MMP7 peptide cross-linked hydrogels with tethered bioactive sequences, and (C) ScrMMP7 peptide cross-linked-hydrogels without tethered bioactive sequences after
exposure to exogenous recombinant human MMP1, 2, 7 and 13 in chondrogenic medium. Degradation was normalized to weight at day 0. Trypsin-driven degradation is positive
control. Chondrogenic medium without exogenous recombinant human MMP7 is negative control. Values are represented as means ± SD (n ¼ 3).
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eleucine cleavage site for MMP7 and have no other recognizable
cleavage site for MMP1, MMP2, MMP7 or MMP13 [44e46], were
only slightly degraded by all MMP enzymes (Fig. 4C). All hydrogels
were signiﬁcantly degraded by trypsin, a highly active and efﬁcient
enzyme that can cleave more sites in the hydrogels [48,49], and at
faster rates compared to the MMP enzymes tested (P < 0.001).
3.4. Cell viability
The viability of hMSCs was maintained at signiﬁcantly higher
levels in the HAbind-MMP7-Scl2, CSbind-MMP7-Scl2, and RGDS-
MMP7-Scl2 hydrogels compared to the MMP7-Scl2 hydrogels
without cell-interactive epitopes (Fig. 5A) (P < 0.001). The DNA
content correlatedwith these results showing a signiﬁcantly higher
cell number in hydrogels with bioactive sequences compared to theMMP7-Scl2 control (Fig. 5B) (P < 0.001). These differences were
expected since the RGDS peptide is known to improve cell adhesion
and the HAbind and CSbind peptides are designed to bind HA and
CS, which are known to improve cell viability [10,19,41]. However,
the viability did decrease slightly throughout the culture period for
these formulations compared to Day 0. This is likely a result of
inefﬁcient diffusion of nutrients, oxygen andwaste products during
long culture times [42] and may be less of a concern under the
cyclic loads present in the joint. The cell viability was further
conﬁrmedwith confocal imaging of the cells within the gels labeled
with the LIVE/DEAD® dyes (Fig. S9).
3.5. In vitro chondrogenesis
The effect of the HAbind and CSbind peptides compared to the
RGDS peptide was evaluated on the chondrogenic differentiation
Fig. 5. hMSC viability in hydrogels. (A) Cell viability in hydrogels cultured over 4 weeks in vitro quantiﬁed using the CellTiter-Glo® assay. (B) DNA content per construct in hydrogels
cultured over 4 weeks in vitro quantiﬁed using a PicoGreen® Kit. All data normalized to day 0. *P < 0.05 (n ¼ 3 for each donor, three different bone marrow-derived hMSC donors).
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drogenic markers, COL2A1, ACAN, and SOX9 (Fig. 6A, B and C), all
indicate the HAbind-MMP7-Scl2 and CSbind-MMP7-Scl2 hydro-
gels signiﬁcantly enhanced chondrogenic differentiation of
hMSCs. These genes were upregulated at all time points compared
to the MMP7-Scl2 and RGDS-MMP7-Scl2 hydrogels (HAbind-
MMP7-Scl2, P < 0.001; CSbind-MMP7-Scl2, P < 0.01). In particular,
the higher concentration of HAbind peptide at 10% functionali-
zation correlated with the highest upregulation of COL2A1, ACAN,
and SOX9 gene expression compared to all other hydrogels
investigated including CSbind-MMP7-Scl2 (P < 0.001). The mea-
sure of a differentiation index (the ratio of COL2A1/COL1A1 gene
expression, Fig. 6F) conﬁrmed the individual gene expression data
observed from COL2A1, ACAN, and SOX9 gene expression as it
remained signiﬁcantly higher for the HAbind-MMP7-Scl2 and
CSbind-MMP7-Scl2 samples throughout the culture period
compared to the MMP7-Scl2 and RGDS-MMP7-Scl2 controls
(HAbind-MMP7-Scl2, P < 0.001; CSbind-MMP7-Scl2, P < 0.05). In
contrast to the RGDS samples, this implied maintenance of the
chondrogenic gene expression proﬁle during the entire culture
period. The HAbind and CSbind peptides showed different extents
of chondrogenic differentiation although they are similarly
charged and have the potential to interact electrostatically with
biomolecules in a similar manner. We previously showed the
HAbind and CSbind peptides can be used to spatially organize HA
and CS respectively in the same scaffold system, which indicates
speciﬁc peptide-GAG interactions beyond electrostatic in-
teractions [10,19]. The presence of the HAbind and CSbind pep-
tides in our hydrogels signiﬁcantly promoted chondrogenesis,
presumably by mimicking protein-GAG interactions in the native
microenvironment.
The gene expression levels of COL1A1 and COL10A1 (Fig. 6D and
E) were signiﬁcantly lower for the HAbind-MMP7-Scl2 and CSbind-
MMP7-Scl2 hydrogels, indicating inhibited or delayed differentia-
tion of hMSCs towards a hypertrophic phenotype throughout the
culture period compared to the RGDS-MMP7-Scl2 and MMP7-Scl2
controls (P < 0.05). Limiting the terminal differentiation of hMSCs
to a hypertrophic phenotype is a critical challenge toward the
clinical use of these cells for articular cartilage regeneration [50]. Inthe native environment, hypertrophic chondrocytes can induce
mineralization of the ECM, leading to inferior function and me-
chanical behavior of the tissue [50]. Previous studies suggested that
the presence of an RGDS peptide sequence may be important
during the early stages of chondrogenesis, but its persistence has
been shown to hinder the differentiation of hMSCs and the extent
of chondrogenesis [13].
The hMSC-seeded hydrogels cultured for 4 weeks in vitro were
also analyzed for collagen, sGAG accumulation, and DNA content.
Total collagen normalized to DNA, sGAG normalized to DNA, and
DNA content were highest for the HAbind(10%)-MMP7-Scl2
hydrogels compared to the other hydrogel formulations (Fig. 7A, B
and C) (P < 0.05), further validating a positive effect of the HAbind
peptide for chondrogenesis. This ﬁnding also translated to signiﬁ-
cantly higher compressive moduli for the HAbind(10%)-MMP7-Scl2
hydrogels compared to the MMP7-Scl2 and RGDS-MMP7-Scl2
controls (Fig. 7D) (P < 0.05). This difference in compressive moduli
may be linked to the HAbind(10%) hydrogel having the highest total
collagen content and collagen-to-sGAG ratio compared to the
MMP7-Scl2 and RGDS-MMP7-Scl2 samples (Fig. S10) (P < 0.05). To
a slightly lesser extent, CSbind-MMP7-Scl2 hydrogels also resulted
in signiﬁcantly increased total collagen and sGAG contents, as well
as increased compressive moduli compared to the MMP7-Scl2 and
RGDS-MMP7-Scl2 hydrogels (P < 0.05). The presence of the HAbind
and CSbind peptides within the hydrogels may have also led to
endogenous recruitment and retention of HA and CS, respectively
[10,19]. These hydrophilic, highly charged GAGs are known to aid in
tissue hydration and contribute to the compressive strength in
native articular cartilage [51].
Histological evaluation of the hydrogels showed a uniform dis-
tribution of cells and ECM production for all hydrogel formulations
after 4 weeks of in vitro culture (Fig. 7E). Extensive sGAG accumu-
lation (Alcian Blue staining) and distribution around encapsulated
cells was more pronounced in the HAbind-MMP7-Scl2 and CSbind-
MMP7-Scl2 hydrogels compared to the MMP7-Scl2 and RGDS-
MMP7-Scl2 controls with less matrix production. Immunohisto-
chemical analysis of collagen type II also correlated with the gene
expression data for all hydrogels. Collagen type II was present in all
hydrogel formulations and was notably higher in the HAbind-
Fig. 6. (A) COL2A1, (B) ACAN, (C) SOX9, (D) COL1A1 and (E) COL10A1 gene expression for hMSCs encapsulated in hydrogels over 4 weeks in vitro, as measured by qPCR and analyzed
using the DDCT method, represented as a fold difference relative to undifferentiated hMSCs (calibrator) prior to encapsulation and normalized to GAPDH. (F) COL2A1/COL1A1 ratio
was high throughout the culture period. Values are represented as means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 (n ¼ 3 for each donor, three different bone marrow-derived hMSC
donors).
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Fig. 7. Collagen and glycosaminoglycan deposition. (A) Total collagen content in hydrogels cultured over 4 weeks quantiﬁed using a hydroxyproline assay. (B) sGAG content in
hydrogels cultured over 4 weeks quantiﬁed using a Blyscan Kit. (C) DNA content per construct in hydrogels cultured over 4 weeks quantiﬁed using a PicoGreen® Kit. (D) Conﬁned
elastic modulus of compression of hydrogels compressed to 10% strain at 0.5% strain/min after 4 weeks of in vitro culture. Values are represented as means ± SD. *P < 0.05, **P < 0.01,
***P < 0.001 (n ¼ 3 for each donor, three different bone marrow-derived hMSC donors). (E) Histological examination of hydrogels after 4 weeks of in vitro culture. Hydrogels are
stained with haematoxylin and eosin (H&E), alcian blue for sGAG, and by IHC for collagen type I, collagen type II and collagen type X, respectively, from top to bottom. All scale bars
represent 200 mm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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MMP7-Scl2 and RGDS-MMP7-Scl2 controls. This corresponded
with the total collagen and sGAG content shown in Fig. 7A and B,
respectively. Staining for collagen type I was low in all hydrogel
formulations while staining for collagen type X, an indicator of
chondrocyte hypertrophy [9], was negative in all hydrogel formu-
lations. This supports our previous ﬁndings and indicated that the
hMSCs were differentiating towards chondrogenesis in the GAG-
binding hydrogels.Fig. 8. Conﬁrmation of MMP7 as an enzyme for bioresponsive hydrogels. (A) MMP7 and (B)
measured by qPCR and analyzed using the DDCT method, represented as a fold difference re
GAPDH. Values are represented as means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 (n ¼ 3 for e
seeded hydrogels correlated to MMP7 activity. (C) Degradation characterized by dry weight
(D) MMP7 activity quantiﬁed in hydrogels cultured over 4 weeks in vitro using an MMP7 ﬂuo
Values are represented as means ± SD (n ¼ 3 for each donor, three different bone marrow3.6. Cell-mediated hydrogel degradation
As the HAbind and CSbind peptides had a signiﬁcant effect on
the differentiation behavior of the hMSCs, we expected to observe
an effect on the gene expression and activity of MMP7 since matrix
remodeling is linked to chondrogenesis. The gene expression of
MMP7 (Fig. 8A) was signiﬁcantly increased in cells encapsulated
within the CSbind-MMP7-Scl2 and HAbind-Scl2-MMP7 hydrogels
compared to other materials (CSbind-MMP7-Scl2; P < 0.001,TIMP2 gene expression for hMSCs encapsulated in hydrogels over 4 weeks in vitro, as
lative to undifferentiated hMSCs (calibrator) prior to encapsulation and normalized to
ach donor, three different bone marrow-derived hMSC donors). Degradation of hMSC-
change of the construct over time. Degradation was normalized to dry weight at day 0.
rogenic substrate assay. MMP7 activity was normalized to ﬂuorescence output at day 0.
-derived hMSC donors).
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upregulated at all time points for the CSbind(10%)-MMP7-Scl2
hydrogels compared to the HAbind-MMP7-Scl2 (P < 0.05), RGDS-
MMP7-Scl2 (P < 0.001), and MMP7-Scl2 (P < 0.001) hydrogels. The
gene expression of TIMP2, a known inhibitor of MMP7 [52],
exhibited a reverse trend with the lowest levels measured in
CSbind(10%)-MMP7-Scl2 hydrogels (Fig. 8B). CS is a highly sulfated
GAG that is thought to enhance the autolytic molecular activation
of proMMP7 and activity of active MMP7 [47]. The CS-binding
peptide may be recruiting and/or interacting with endogenous CS
produced by the differentiating hMSCs to promote the gene
expression and activity of MMP7 [10,47]. The weight loss observed
for the CSbind-MMP7-Scl2 hydrogels also supports this difference
in MMP7 gene expression and activity (Fig. 8C). In contrast to the
acellular degradation kinetics that showed similar degradation
rates to theMMP7-Scl2 control in the presence of exogenousMMP7
for both the HAbind-MMP7-Scl2 and CSbind-MMP7-Scl2 hydro-
gels, the degradation of the cell-seeded CSbind-MMP7-Scl2
hydrogels were signiﬁcantly greater (45 ± 4.6%), with higher ac-
tivity of endogenous MMP7 after 4 weeks in vitro compared to the
HAbind-MMP7-Scl2, MMP7-Scl2, and RGDS-MMP7-Scl2 hydrogels
(Fig. 8D) (P < 0.05). Initially, the construct weight reduction was
signiﬁcantly higher for the CSbind-MMP7-Scl2 hydrogels
compared to the other hydrogels (P < 0.05), suggesting that it was
primarily mediated by the degradation of the hydrogel via endog-
enous MMP7 rather than the accumulation of matrix. This posi-
tively correlated with the MMP7 gene expression and activity data
where MMP7 gene expression and activity were signiﬁcantly
higher for the CSbind-MMP7-Scl2 hydrogels compared to the other
hydrogels. Taken together, the chondrogenesis and biodegradation
results suggest the potential to combine the HAbind and CSbind
peptides within a single hydrogel system using the Scl2 protein
backbone to impart improved control over the rates of matrix
accumulation and hydrogel degradation.
The compressive moduli of the cell-seeded HAbind-MMP7-Scl2
and CSbind-MMP7-Scl2 hydrogels (Fig. 7D) did not change
signiﬁcantly compared to their acellular counterparts (Fig. 3C)
after 4 weeks despite the signiﬁcant construct weight reduction.
Our data showed that both hydrogels accumulated a signiﬁcantly
greater amount of sGAG matrix compared to the MMP7-Scl2 and
RGDS-MMP7-Scl2 hydrogels after 4 week in vitro (Fig. 7B), which
likely contributed to the compressive moduli of the hydrogels.
Interestingly, the weight of the HAbind-MMP7-Scl2 and CSbind-
MMP7-Scl2 constructs was signiﬁcantly lower compared to the
MMP7-Scl2 and RGDS-MMP7-Scl2 constructs. However, taken
together with the sGAG data, these results suggest the higher sGAG
accumulation in the HAbind-MMP7-Scl2 and CSbind-MMP7-Scl2
constructs may be contributing to the compressive moduli. By
Week 4, there was a plateau in the construct weight change (Fig. 8)
for the HAbind-MMP7-Scl2 and CSbind-MMP7-Scl2 hydrogels
compared to the MMP7-Scl2 and RGDS-MMP7-Scl2 hydrogels,
suggesting a balance between the degradation of the hydrogel and
the accumulation of matrix that is supported by the total collagen
and sGAG accumulation data (Fig. 7). In addition, the MMP7 con-
centration used in the acellular degradation studies was consid-
erably higher (30 ng/mL) than physiological levels (0.3 ng/mL) [44]
to accelerate the overall degradation. At physiological levels, it is
expected that the construct weight change for all hydrogel for-
mulations would be more strongly affected by the matrix accu-
mulation than the hydrogel degradation over a longer incubation
period. Hydrogels cross-linked via MMP-cleavable peptides have
demonstrated cell-mediated degradation that plays a role in
cellular processes such as chondrogenesis and differentiation
[13,20,53,54]. In our work, incorporating GAG-binding motifs
within the hydrogels is shown to regulate MMP7 gene expressionand activity and, arguably, the chondrogenic differentiation of
encapsulated hMSCs.
The combination of MMP-cleavable cross-links and the bioac-
tive components introduces the possibility to mediate inherent
biological processes to guide the dynamics of tissue regeneration
and remodeling. Incorporating varying ratios of the HAbind and
CSbind peptide motifs in a single hydrogel can be used to tune the
kinetics of chondrogenesis and ECM accumulation to match the
rate of cell-mediated hydrogel degradation. In addition, the
modularity allows for other MMP-sensitive peptides and bioactive
sequences to be added easily through tethering or site-directed
mutagenesis to the collagen-like protein backbone to recreate the
complexity of the ECM and mimic zone-speciﬁc microenviron-
ments. This is particularly useful when optimizing the hydrogel for
in vivo translation where the potentially inﬂammatory and native
ECM interactions could induce unintended protease activities. This
novel collagen-like protein-based design provides a platform that
can also be readily adapted with multiple and selected peptide
sequences for desired applications in other areas of regenerative
medicine.4. Conclusions
We have designed and developed novel biodegradable hydro-
gels based on recombinant collagen-mimetic Scl2 proteins that can
be easily tailored to recreate the biochemical microenvironment of
articular cartilage. The blank slate Scl2 protein was tethered with
GAG-binding peptides speciﬁc for HA and CS and cross-linked into
an injectable hydrogel with MMP7-sensitive peptide for cell-
mediated degradation. The presence of the GAG-binding peptides
signiﬁcantly enhanced the chondrogenic characteristics of the
constructs encapsulated with hMSCs. Speciﬁcally, the HAbind-
MMP7-Scl2 hydrogels directed the highest increase in the gene
expression of COL2A1, ACAN, and SOX9 by hMSCs leading to the
greatest total collagen and sGAG accumulation. The CSbind-MMP7-
Scl2 hydrogels had the greatest impact on the gene expression and
activity of endogenous MMP7 that correlated with the greatest
change in the articular cartilage deposition/degradation ratio.
Taken together, our hydrogels demonstrate a high degree of
modularity, highlighting the potential to incorporate multiple
peptides to recreate the complex dynamics of native ECM, and
introduce a minimally invasive approach to promote chondro-
genesis with host MSCs.Acknowledgments
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